Učitavanje...
Prevention of COPD exacerbation by lysozyme: a double-blind, randomized, placebo-controlled study
BACKGROUND/AIM: Lysozyme (mucopeptide N-acetyl-muramyl hydrolase) is widely used as a mucolytic and anti-inflammatory agent in Japan. We evaluated the effects of long-term lysozyme administration on COPD exacerbation. METHODS: In a 1-year, randomized, double-blind, placebo-controlled, parallel trial...
Spremljeno u:
| Izdano u: | Int J Chron Obstruct Pulmon Dis |
|---|---|
| Glavni autori: | , , , , , , , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
Dove Medical Press
2016
|
| Teme: | |
| Online pristup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4846053/ https://ncbi.nlm.nih.gov/pubmed/27143873 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/COPD.S103105 |
| Oznake: |
Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|